Patten S B, Neutel C I
Department of Community Health Sciences, Faculty of Medicine, The University of Calgary, Alberta, Canada.
Drug Saf. 2000 Feb;22(2):111-22. doi: 10.2165/00002018-200022020-00004.
Reports of corticosteroid-induced adverse psychiatric effects began to appear in the literature soon after the introduction of these medications in the 1950s. Unfortunately, early studies relied on informal classification and measurement procedures and tended to utilise nonspecific descriptive terminology (such as steroid psychosis'). A growing number of contemporary investigations have begun to address these problems. However, the literature remains surprisingly undeveloped from a pharmacoepidemiological perspective, consisting largely of case reports and case series. The objective of this review is to summarise published data concerning corticosteroid-induced adverse psychiatric effects. A clinical perspective will be adopted since opportunities to minimise the impact of corticosteroid-induced adverse effects tend to present themselves most readily within the sphere of clinical management. Some of the psychiatric adverse effects of corticosteroids are mild, and not necessarily clinically significant. However, several serious psychiatric syndromes can be caused by corticosteroids: substance-induced mood disorders (with depressive, manic and mixed features), substance-induced psychotic disorders and delirium. While certain clinical groups may be at greater risk of corticosteroid-induced adverse psychiatric effects, corticosteroid-induced psychiatric toxicity is remarkably unpredictable. The literature regarding prevention and treatment of corticosteroid-induced adverse psychiatric effects is poorly developed. As a result, the emphasis of this review is on clinical and epidemiological evidence linking specific adverse effects to corticosteroid medications. However, clinical reports do provide some practical guidance for prevention and treatment, and these are summarised as well. A variety of pharmacological strategies for treatment and prevention have been proposed. Education and support also appear to be important, and perhaps neglected.
20世纪50年代这些药物问世后不久,有关皮质类固醇引起不良精神影响的报告便开始出现在文献中。不幸的是,早期研究依赖于非正式的分类和测量程序,且倾向于使用非特定的描述性术语(如“类固醇精神病”)。越来越多的当代研究已开始着手解决这些问题。然而,从药物流行病学角度来看,该文献仍惊人地不发达,主要由病例报告和病例系列组成。本综述的目的是总结已发表的关于皮质类固醇引起不良精神影响的数据。将采用临床视角,因为在临床管理领域往往最容易出现将皮质类固醇引起的不良反应影响降至最低的机会。皮质类固醇的一些精神不良反应较轻,不一定具有临床意义。然而,皮质类固醇可引发几种严重的精神综合征:物质所致心境障碍(具有抑郁、躁狂和混合特征)、物质所致精神障碍和谵妄。虽然某些临床群体可能更易出现皮质类固醇引起的不良精神影响,但皮质类固醇引起的精神毒性非常难以预测。关于皮质类固醇引起不良精神影响的预防和治疗的文献发展不足。因此,本综述的重点是将特定不良反应与皮质类固醇药物联系起来的临床和流行病学证据。然而,临床报告确实为预防和治疗提供了一些实用指导,本文也对这些指导进行了总结。已经提出了多种治疗和预防的药理学策略。教育和支持似乎也很重要,或许被忽视了。